Relmada Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -10,091 | -10,221 | -18,218 | -18,657 |
EBIT | -38,152 | |||
Net Income | -10,091 | -9,866 | -17,559 | -18,657 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -6,721 | -6,401 | -18,067 | -8,799 |
Cash | 1,384 | 1,353 | 1,149 | 3,857 |
Basic Shares | 33,191 | 33,191 | 30,409 | 30,174 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1 | |||
EBITDA | -83,891 | 4,910 | -161,247 | -125,702 |
EBIT | -79,979 | -98,792 | -161,249 | -125,703 |
Net Income | -79,979 | -98,792 | -157,043 | -125,751 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -39,047 | |||
Free Cash Flow | -51,755 | -51,659 | -103,801 | -91,873 |
Cash | 3,857 | 4,091 | 5,395 | 44,443 |
Basic Shares | 30,164 | 30,099 | 29,629 | 17,552 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.30 |
2025-06-30 | -$0.30 |
2025-03-31 | -$0.58 |
